CRISPR Therapeutics Names A.J. Silver CFO as Raju Prasad Departs

CRISPR Therapeutics Inc. (CRSP) said Chief Financial Officer Raju Prasad will step down to pursue other opportunities, with Senior Vice President of Finance A.J. Silver succeeding him as CFO effective immediately. Silver has served as SVP of Finance since January 2025 and has held leadership roles across strategic finance, treasury, financial planning and analysis, accounting, tax and financial operations since joining the company in 2018. He previously spent more than a decade at Ernst & Young LLP, where he qualified as a Certified Public Accountant. The company's CASGEVY gene-edited cell therapy generated revenue of $76 million in the second quarter of 2026. Net loss for the quarter was $91.2 million, compared with a net loss of $208.5 million a year earlier. Cash, cash equivalents and marketable securities totaled $2.36 billion as of June 30, 2026. CRSP closed Monday's trade at $50.04, up 1.60%, and was recently down 0.86% at $49.61.